Erlotinib Plus Bevacizumab in EGFR-Mutant NSCLC

November 18, 2016
Special Reports, NSCLC (Issue 11), Volume 4, Issue 2

Howard L. &ldquo;Jack&rdquo; West, MD, thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the combination of erlotinib plus bevacizumab (Avastin) as a frontline treatment for patients with unresectable advanced, metastatic, or recurrent&nbsp;<em>EGFR</em>-mutant non-small cell lung cancer (NSCLC).

Howard L. “Jack” West, MD, thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the combination of erlotinib plus bevacizumab (Avastin) as a frontline treatment for patients with unresectable advanced, metastatic, or recurrentEGFR-mutant non-small cell lung cancer (NSCLC).

While not yet available for use in the United States, the European Medicines Agency approved the combination in June 2016 and West says he regularly uses it.